Adverse effects of prolonged use of non-steroidal anti-inflammatory drugs that inhibit COX-2 in horses: review
Keywords:Analgesia; NSAID; Horse; Pain; Time of use
Non-steroidal anti-inflammatory drugs (NSAIDs), being freely marketed, are among the most prescribed drugs in the world, have anti-inflammatory, analgesic and antipyretic action by inhibiting prostaglandins by blocking cycloxygenases (COX). Currently, it is known that there are three COX enzymes with different actions. It has been postulated that the pharmacological properties of NSAIDs stem mainly from the inhibitory action of COX-2, while adverse reactions are the result of COX-1 inhibition, creating subgroups of NSAIDs: preferential, selective and non-selective for COX-2. The introduction of COX-2 inhibitors in clinical practice aims to maintain anti-inflammatory efficacy without undesirable adverse effects. However, studies suggest toxicity associated with its use. The objective of this word is to gather information about the side effects of the prolonged use of NSAIDs that inhibit COX-2 in the equine species. For this, a bibliographic review was carried out looking for studies on the effects of the use of COX-2 inhibitors in horses. It was observed that this class of drugs has several toxic effects for the species, mainly in situations where there have been overdoses, prolonged use and association with other NSAIDs. Control measures are needed in the commercialization of these drugs. The choice of drug for treatment must be individualized for each patient, taking into account their risk factors and benefits. Its rational use is an important ally of veterinary clinicians in promoting animal health and well-being.
Alonso, J.M., Filho, P.T.H., Ávila, A.R., Machado, V.M.V., Hataka, A., Bueno, L.M.C., Alves, A.L.G., Hussni, C.A., Rodrigues, C.A. & Watanabe, M.J. (2019). Surgical Repair of an Occipital Meningocele in a Foal. Journal of Equine Veterinary Science, 81:102771.
Anon. (2009). Survey Shows Nearly All Horse Owners, Trainers Administer Nonsteroidal Anti-inflammatory, Merial Press Release, 29th April.
AVMA. (2020). Clarification regarding substitution of Previcox for Equi¬oxx. Acesso em 01 de junho de 2020: https://www.avma.org/javma-news/2010-06-15/extralabel-drug-substitution-runs-afoul-law.
Banse, H. & Cribb, A.E. (2017). Comparative efficacy of oral meloxicam and phenylbutazone in 2 experimental pain models in the horse. The Canadian Veterinary Journal, 58(2):157–167.
Barry, S. (2010). Non-steroidal anti-inflammatory drugs inhibit bone healing: a review. Veterinary and Comparative Orthopaedics and Traumatology, 23(6): 385–92.
Bessoni, F. (2011). Hepatotoxidade pelos AINEs. GED Gastroenterologia Endoscopia Digestiva, 30(1):06-47.
Bergh, M.S. & Budsberg, S.C. (2005). The Coxib NSAIDs: potential clinical and pharmacologic importance in veterinary medicine. Journal of Veterinary Internal Medicine, 19(5):633-643.
Beretta, C., Garavaglia, G. & Cavalli, M. (2007). COX-1 and COX-2 inhibition in horse blood by phenylbutazone, flunixin, carprofeno and meloxicam: an in vitro analysis. American Journal Veterinary Research, 68(3):258-262.
Carvalho, W.A., Carvalho, R.D.S. & Rios-Santos, F. (2004).Analgésicos inibidores específicos da COX-2: avanços terapêuticos. Revista brasileira de anestesiologia, 54(3):448-464.
Chan, C.C., Reid, C.M., Aw, T.J., Liew, D., Haas, S.J. & Krum, H. (2009). Do COX-2 inhibitors raise blood pressure more than nonselective NSAIDs and placebo? An update meta-analysis. Journal of Hypertension, 27(12):2332–2341.
Cunha, M.E.N., Silva, E.N., Abreu, D.B., Dias, D.C.R. & Ayres, M.C.C. (2019). Uveíte bilateral em um equino: relato de caso. Pubvet. 13(1), a252:1-8.
Cook, V.L. & Blikslager, A.T. (2014). The use of nonsteroidal anti-inflam¬matory drugs in critically ill horses. Journal of Veterinary Emergency and Critical Care, 25(1):76–88.
Cook, V.L., Meyer, C.T., Campbell, N.B. & Blikslager, A.T. (2009). Effect of firocoxib or flunixin meglumine on recovery of ischemic-injured equine jejunum. American Journal of Veterinary Research, 70(8):992-1000.
Farias, P.O. (2016). Aspectos epidemiológicos das intoxicações por analgésicos não opioides e anti-inflamatórios não esteroides em um hospital de urgência e emergência da rede pública do Brasil. Revista Médica de Minas Gerais, 26(5):11-15.
FDA (Food and Drug Administration). (2005). Equioxx oral paste, Merial®. Freedom of information summary, NADA 141-253. Disponível em: https://animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadFoi/805 .
Friso, A.M., Segabinazzi, L.G.T.M., Cyrino, M., Correal, S.B., Dell’Aqua, C.P.F., Carmo MT, Dell'Aqua Jr, J.A., Miro, J., Papa, F.O. & Alvarenga, M.A. (2019). Periovulatory administration of firocoxib did not alter ovulation rates and mitigated post-breeding inflammatory response in mares. Theriogenology, 138, 24-30.
Gerstenfeld, L.C., Al-Ghawas, M., Alkhiary, Y.M., Cullinane, D.M., Krall, E.A., Fitch, J.L., Webb, E.G., Thiede, M.A. & Einhorn, T.A. (2007). Selective and nonselective cyclooxygenase-2 inhibitors and experimental fracture-healing. Reversibility of effects after short-term treatment. Journal of Bone and Joint Surgery. American volume, 89(1):114–125.
Hovanessian, N., Davis, J.L., Mckenzie III, H.C., Hodgson, J.L., Hodgson, D.R. & Crisman, M.V. (2013). Journal of Veterinary Pharmacology and Therapeutics, 37:243-251.
Kivett, L., Taintor, J. & Wright, J. (2014). Evaluation of the safety of a com¬bination of oral administration of phenylbutazone and firo¬coxib in horses. Journal of Veterinary Pharmacoly and Therapeutics, 37(4):413–416.
Knych, H.K. (2017). Nonsteroidal anti-inflamatory drug use in horses. Veterinary Clinics of North America: Equine Pratice, 33(1):1-15.
Mendes, R.T., Stanczyk, C.P., Sordi, R., Otuki, M.F., Santos, F.A. & Fernandes, D. (2012). Inibição seletiva da ciclo-oxigenase-2: riscos e benefícios. Revista Brasileira de Reumatologia, 52(5):767-782.
Modi, C.M., Mody, S.K., Patel, H.B., Dudhatra, G.B., Kumar, A. & Avale, M. (2012). Toxicopathological overview of analgesic and anti-inflammatory drugs in animals. Journal of Applied Pharmaceutical Science, 2(1):149-157.
Nakagawa, K., Yamagami, T. & Takemura, N. (2005). Hepatocellular toxicosis associated with the alternate administration of carprofen and meloxicam in a Siberian Husky. Journal of Veterinary Medical Science, 67(10):1051-1053.
Noble, G., Edwards, S., Lievaart, L., Pippia, J., Boston, R. & Raidal, S.L. (2012). Pharmacokinetics and Safety of Single and Multiple Oral Doses of Meloxicam in Adult Horses. Journal of Veterinary Internal Medicine, 26(5):1192–1201.
Okada, C.T.C., Andrade, V.P., Dell’Aqua, C.P.F., Nichi, M., Fernandes, C.B., Papa, F.O. & Alvarenga, M.A. (2018). The effect of flunixin meglumine, firocoxib and meloxicam on the uterine mobility of equine embryos, Theriogenology, 123:132-138.
Pereira, A.S., Shitsuka, D.M., Parreira, F.J. & Shitsuka, R. (2018). Metodologia da pesquisa científica. [e-book]. Santa Maria. Ed. UAB/NTE/UFSM. Disponível em: https://repositorio.ufsm.br/bitstream/handle/1/15824/Lic_Computacao_MetodologiaPesquisa-Cientifica.pdf?sequence=1.
Raidal, S.L., Edwards, S., Pippia, J., Boston, R. & Noble, G.K. (2013). Pharmacokinetics and safety of oral administration of meloxicam to foals. Journal of Veterinary Internal Medicine, 27(2):300–7.
Ryan, W.G., Moldave, K. & Carithers, D. (2006). Clinical effectiveness and safety of a new NSAID, firocoxib: A 1,000 dog study. Veterinary Therapeutics, 7(2):119-126.
Santos Júnior, D.A., Assis, D.M., Costa, A.H.C., Pereira, C.S., Bastos, R.M. & Miranda Neto, E.G. (2018). Fratura de osso sacro em equino de vaquejada: relato de caso. Revista Brasileira de Medicina Equina, 13(79):14-16.
Santos, R.S.T., Pereira, M.A.A., Garcia Filho, S.G., Spagnolo, J.D., Ambrosio, A.M. & Fantoni, D.T. (2018). Correlação entre o uso de anti-inflamatórios não esteroidais e efeitos adversos em equinos: revisão bibliográfica. Revista Brasileira de Medicina Equina, 13:14-22.
Savage, V.L., Marr, C.M., Bailey, M., Smith, S. (2019). Prevalence os acute kidney injuri in a population of hospitalized horses. Journal of Veterinary Internacional Medice, 33:2294-2301.
Schott II, H.C. & Esser, M.M. (2019). The sick adult horse renal clinical pathologic testing and urinalysis. Veterinary Clinics of North America: Equine Practice, 36(1):121-134.
Silva, G.B., De La Corte, F.D., Brass, K.E., Fialho, S.S. & Pereira, R.C.F. (2013). Laminite crônica em equídeos da raça Crioula: características clínicas e radiográficas. Ciência Rural, 43(11):2025-2030.
Shi, S. & Klotz, U. (2008). Clinical use and pharmacological properties of selective COX-2 inhibitors. European Journal of Clinical Pharmacology, 64(3):233–52.
Souto, E.O., Miyoshi, H., Dubois, R.N. & Gores, G.J. (2001). Kupffer cellderived cyclooxygenase-2 regulates hepatocyte Bcl-2 expression in choledocho-venous fistula rats. American Journal of Physiology – Gastrointestinal and Liver Physiology, 280(5):805-811.
Tomlinson, J.E., Wilder, B.O., Young, K.M. & Blikslager, A.T. (2004). Effects of flunixin meglumine or etodolac treatment on mucosal recovery of equine jejunum after ischemia. American Journal of Veterinary Research, 65(6):761–769.
Van Eps, A.W. (2010). Acute Laminitis: Medical and Supportive Therapy. Veterinary Clinics of North America - Equine Practice, 26(1):103–114.
Veronezi, R.C., Nunes, P.G., Cassol, D.M.S., Toma, S.B., Thomassian, A. & Alves, A.L.G. (2006). Avaliação da eficácia e segurança do meloxicam administrado por via oral em equinos. Revista Brasileira de Medicina Equina, 1(4):11-17.
Werk, K.A.V., Davis, E.G. & Kukanich, B. (2012). Pharmacokinetics and adverse effects of oral meloxicam tablets in healthy adult horses. Journal of Veterinary Pharmacology Therapeutics, 36(4):376-81.
Ziegler, A., Fogle, C. & Blikslager, A. (2017). Update on the use of cyclooxygenase-2–selective nonsteroidal anti-inflammatory drugs in horses. Review article. Journal of the American Veterinary Medical Association, 250(11):1271-1274.
How to Cite
Copyright (c) 2020 Dinamérico de Alencar Santos Júnior; Emanuel Felipe de Oliveira Filho; Eldinê Gomes de Miranda Neto; Pierre Barnabé Escodro
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.